Literature DB >> 32042636

Bacillus Calmette Guérin in bladder cancer: is more immune stimulation better?

Mar Valés-Gómez1.   

Abstract

Entities:  

Year:  2019        PMID： 32042636      PMCID： PMC6989848          DOI： 10.21037/tau.2019.12.23

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN： 2223-4683


× No keyword cloud information.
  25 in total

1.  Characterization of a human anti-tumoral NK cell population expanded after BCG treatment of leukocytes.

Authors:  Eva M García-Cuesta; Gloria Esteso; Omodele Ashiru; Sheila López-Cobo; Mario Álvarez-Maestro; Ana Linares; Mei M Ho; Luis Martínez-Piñeiro; Hugh T Reyburn; Mar Valés-Gómez
Journal:  Oncoimmunology       Date:  2017-02-21       Impact factor: 8.110

2.  High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis.

Authors:  Kai Qu; Jian Gu; Yuanqing Ye; Stephen B Williams; Colin P Dinney; Xifeng Wu; Ashish Kamat
Journal:  Oncoimmunology       Date:  2017-01-03       Impact factor: 8.110

3.  Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin.

Authors:  Ashish M Kamat; Joseph Briggman; Diana L Urbauer; Robert Svatek; Graciela M Nogueras González; Roosevelt Anderson; H Barton Grossman; Ferran Prat; Colin P Dinney
Journal:  Eur Urol       Date:  2015-06-25       Impact factor: 20.096

4.  Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer.

Authors:  E C de Boer; L Somogyi; G J de Ruiter; T M de Reijke; K H Kurth; D H Schamhart
Journal:  Urol Res       Date:  1997

5.  Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer.

Authors:  Aurélie Bisiaux; Nicolas Thiounn; Marc-Olivier Timsit; Ahmed Eladaoui; Huey-Hsuan Chang; James Mapes; Agnès Mogenet; Jean-Louis Bresson; Dominique Prié; Stéphane Béchet; Camille Baron; Christine Sadorge; Stéphanie Thomas; Elaine B Albert; Peter S Albert; Matthew L Albert
Journal:  J Urol       Date:  2009-02-23       Impact factor: 7.450

6.  Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation.

Authors:  Henrik Suttmann; Marc Jacobsen; Karina Reiss; Dieter Jocham; Andreas Böhle; Sven Brandau
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

7.  Development of bacillus Calmette-Guérin-induced antitumor activity in peripheral blood mononuclear cells.

Authors:  S Koga; K Taniguchi; M Nishikido; S Kubota; S Yamashita; H Kanetake; Y Saito
Journal:  Urol Int       Date:  1991       Impact factor: 2.089

8.  Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity.

Authors:  A Shapiro; T L Ratliff; D M Oakley; W J Catalona
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

9.  Bacillus Calmette-Guérin (BCG) vaccine: A global assessment of demand and supply balance.

Authors:  Tania Cernuschi; Stefano Malvolti; Emily Nickels; Martin Friede
Journal:  Vaccine       Date:  2017-12-15       Impact factor: 3.641

10.  BCG Therapy of Bladder Cancer Stimulates a Prolonged Release of the Chemoattractant CXCL10 (IP10) in Patient Urine.

Authors:  Omodele Ashiru; Gloria Esteso; Eva M García-Cuesta; Eva Castellano; Celia Samba; Eva Escudero-López; Sheila López-Cobo; Mario Álvarez-Maestro; Ana Linares; Mei M Ho; Asier Leibar; Luis Martínez-Piñeiro; Mar Valés-Gómez
Journal:  Cancers (Basel)       Date:  2019-07-04       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.